Literature DB >> 4105896

The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH582) on benign prostatic hypertrophy.

D A Aubrey, T Khosla.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4105896     DOI: 10.1002/bjs.1800580904

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


× No keyword cloud information.
  4 in total

Review 1.  Benign prostatic hyperplasia: the best treatment.

Authors:  G D Chisholm
Journal:  BMJ       Date:  1989-07-22

2.  Medical treatment of enlarged prostate.

Authors: 
Journal:  Br Med J       Date:  1971-12-11

3.  Gestronol hexanoate (SH582) and benign prostatic hypertrophy.

Authors:  A G Pitchford
Journal:  Proc R Soc Med       Date:  1972-02

4.  Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Authors:  Weiqiang Li; Robert J Klein
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-11-20       Impact factor: 5.554

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.